Size indication Clause Samples

Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 8 Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 125 >125 Dummy Q0 Q1 Q1.5 Q32 Q6 Q101 1 No lateral impact test using the Q10 dummy is required for i-Size booster seats with a size range upper limit between 125 cm and 135 cm. 2 ECRS shall not be approved only on the base of Q3 test results in non-integral configuration Where the Enhanced Child Restraint System requires substantial modification for different sizes (e.g., convertible Enhanced Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above. 7.1.3.6.1. If the Enhanced Child Restraint System is designed for two or more children, one test shall be carried out with the heaviest dummies occupying all seating positions. A second test with the lightest and the heaviest dummies specified above shall be carried out. The tests shall be conducted using the test bench as shown in Annex 6, Appendix 3, Figure 3. The laboratory conducting the tests may, if it deems it advisable, add a third test with any combination of dummies or empty seat positions. 7.1.3.6.2. If the i-Size Enhanced Child Restraint System uses a top tether, one test shall be carried out with the smallest dummy with the shorter distance of the top tether (anchorage point G1). A second test shall be carried out with the heavier dummy with the longer distance of the top tether (anchorage point G2). Adjust the top tether to achieve a tension load of 50  5 N. For side lateral impact the ISOFIX Enhanced Child Restraint System shall be tested with only the shorter distance of the top tether. 7.1.3.6.3. If the i-Size Enhanced Child Restraint System uses a support-leg, as an anti-rotation device the hereafter mentioned dynamic tests shall be carried out as follows: (a) The tests for frontal impact shall be conducted with the support-leg adjusted to its maximum adjustment compatible with the positioning of the trolley floor pan. The tests for rear impact shall be conducted with the worst case position selected by the Technical Service. During the tests the support-leg shall be supported by the trolley floor pan as described in Annex 6, Appendix 2, Figure 2; (b) In the case of support-legs o...
View SourceView Similar (11)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System.
View SourceView Similar (7)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 7 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 135 >135 Dummy Q0 Q1 Q1.5 Q3 Q6 Q101 1 No lateral impact test is required for size range over 135 cm until Q10 dummy injury criteria for the lateral impact test are established. Where the Enhanced Child Restraint System requires … defined above." Paragraph 7.1.3.6.3., amend to read:
View SourceView Similar (3)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Child Restraint System. Table 3, Selection criteria for the dummy according to the range Table 3 Dummy Q0 Q1 Q 1.5 Q3 Q6 Q10 Where the Child Restraint System requires substantial modification for different sizes (e.g., convertible Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above. If the Child Restraint System is designed for two or more children, one test shall be carried out with the heaviest dummies occupying all seating positions. A second test with the lightest and the heaviest dummies specified above shall be carried out. The laboratory conducting the tests may, if it deems it advisable, add a third test with any combination of dummies or empty seat positions.
View SourceView Similar (2)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Where the Enhanced Child Restraint System requires substantial modification for different sizes (e.g., convertible Enhanced Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above. 7.1.3.6.1. If the Enhanced Child Restraint System is designed for two or more children, one test shall be carried out with the heaviest dummies occupying all seating positions. A second test with the lightest and the heaviest dummies specified above shall be carried out. The tests shall be conducted using the test bench as shown in Annex 6, Appendix 3, Figure 3. The laboratory conducting the tests may, if it deems it advisable, add a third test with any combination of dummies or empty seat positions. 7.1.3.6.2. If the i-Size Enhanced Child Restraint System uses a top tether, one test shall be carried out with the smallest dummy with the shorter distance of the top tether (anchorage point G1). A second test shall be carried out with the heavier dummy with the longer distance of the top tether (anchorage point G2). Adjust the top tether to achieve a tension load of 50 ± 5 N. For side lateral impact the ISOFIX Enhanced child restraint shall be tested with only the shorter distance of the top tether.
View Source
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 7 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 125 >125 1 No lateral impact test using the Q10 dummy is required for i-Size booster seats with a size range upper limit between 125 cm and 135 cm. 2 ECRS shall not be approved only on the base of Q3 test results in non-integral configuration Where the Enhanced Child Restraint System requires … defined above." Paragraphs 7.3. to 7.3.3., amend to read:
View Source

Related to Size indication

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.